Details

Autor(en) / Beteiligte

• Talal El Zarif
• Nassar, Amin
• Adib, Elio
• Fitzgerald, Bailey
• Huang, Jiaming
• Mouhieddine, Tarek
• Taylor Nonato
• McKay, Rana
• Li, Mingjia
• Mittra, Arjun
• Owen, Dwight
• Lorentsen, Michael
• Dittus, Christopher
• Dizman, Nazli
• Emu, Brinda
• Adewunmi Falohun
• Abdel-Wahab, Noha
• Bankapur, Anand
• Reed, Alexandra
• Dobbs, Ryan
• Kim, Chul
• Arora, Aakriti
• Shah, Neil
• El-Am, Edward
• Kozaily, Elie
• Abdallah, Wassim
• Al-Hader, Ahmad
• Batool Abu Ghazal
• Anwaar Saeed
• Drolen, Claire
• Lechner, Melissa
• Espinar, Javier
• Nebhan, Caroline
• Johnson, Douglas
• Haykal, Tarek
• Morse, Michael
• Cortellini, Alessio
• Pinato, David
• Alessia Dalla Pria
• Bower, Mark
• Hall, Evan
• Bakalov, Veli
• Bahary, Nathan
• Rajkumar, Aarthi
• Mangla, Ankit
• Shah, Vishal
• Singh, Parminder
• Frank Aboubakar Nana
• Lia, Nerea Lopetegui
• Dima, Danai
• Funchain, Pauline
• Saleem, Rabia
• Woodford, Rachel
• Long, Georgina
• Menzies, Alexander
• Genova, Carlo
• Barletta, Giulia
• Puri, Sonam
• Florou, Vaia
• Dame Idossa
• Queirolo, Paola
• Lamberti, Giuseppe
• Addeo, Alfredo
• Bersanelli, Melissa
• Freeman, Dory
• Xie, Wanling
• Ramaswami, Ramya
• Marron, Thomas
• Choueiri, Toni
• Lurain, Kathryn
• Baden, Lindsey
• Sonpavde, Guru
• Abdul Rafeh Naqash

Titel

437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium

Ist Teil von

• Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A457-A458

Ort / Verlag

London: BMJ Publishing Group LTD

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• BackgroundDue to limited inclusion of PLWH in most ICI clinical trials, there is a paucity of data evaluating their safety and efficacy in this unique population, especially among PLWH and metastatic NSCLC.MethodsIn this retrospective, international multi-center study, we identified 64 HIV positive (HIV+) patients and 117 matched HIV negative (HIV-) controls with metastatic NSCLC treated with ICI between January 2015 and October 2021 at 16 institutions in the U.S. and Europe. At each institution, we matched 1 HIV+ patient to 2 or 1 HIV- controls (1:2 or 1:1 ratio) by age, sex, class of ICI, use of concurrent chemotherapy, and number of prior lines of systemic therapy. We estimated overall survival (OS) and progression-free survival (PFS) by the Kaplan-Meier method. When the proportional hazards assumption was violated, we used restricted mean survival time (RMST) to compare survival outcomes. We fitted a linear regression model with RMST as outcome and HIV infection as predictor, adjusting for race, ECOG performance status, histology, smoking status and PD-L1 expression. We compared categorical variables using chi-square tests.ResultsIn our cohort, median age was 60 years, 77% were males, 61% received ICI as 1st line therapy, 89% received anti-PD-1 based therapy, and 46% received concurrent chemotherapy. Blacks/African Americans were more represented among HIV+ vs. HIV- patients (42% vs 23%, p <0.01). At baseline, HIV+ patients had a median CD4 count = 386 cells/uL (range: 6 – 1,721), 19/31 had undetectable HIV viral load (VL) while 12/31 had a median detectable VL= 60 copies/mL (range: 10 – 223,408). Grade ≥3 immune-related adverse events occurred in 11% HIV+ vs. 9% HIV- patients. Overall response rate was similar between both groups (28% HIV+ vs. 37% HIV-, p=0.25). Comparing HIV+ vs. HIV- pts, the adjusted RMST difference within 42 months was 1.75 months (95% CI: -4.13, 7.63, p=0.56) for OS, and 0.35 months (95% CI: -4.83, 5.53, p=0.90) for PFS (figures 1 and 2). In addition, the 24-month OS rates were 41.7% for HIV+ vs. 42.9% for HIV- patients while the 24-month PFS rates were 18.1% HIV+ vs 18.7% HIV- patients.Abstract 437 Figure 1Kaplan-Meier curves for Overall Survival stratified by HIV status[Figure omitted. See PDF]Abstract 437 Figure 2Kaplan-Meier curves for Progression-Free Survival stratified by HIV status[Figure omitted. See PDF]ConclusionsIn this matched cohort study, PLWH and metastatic NSCLC had similar toxicity profiles and clinical outcomes to HIV- counterparts receiving ICI supporting their use in PLWH and their inclusion in clinical trials. Larger prospective studies are needed to inform a broader usage of ICI among PLWH presenting with other cancer types, low CD4 counts (i.e., <200 cells/uL) and high VL.Ethics ApprovalOur study was exempt from institutional review board (IRB) review at DFCI (Protocol #21-342) and was approved by local IRBs at participating sites per institutional policy, according to the principles of the Declaration of Helsinki.